MedTrace Logo

Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA

NCT04698330 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2022-02-25

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the effects of oral berberine (BBR) and inulin combined with insulin therapy on diabetes care in patients with LADA.

Conditions

  • Type 1 Diabetes Mellitus
  • Autoimmune Diabetes

Interventions

DRUG

Berberine

0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months

DRUG

Inulin

0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months

DRUG

Berberine placebo tablets

0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months

DRUG

Inulin placebo tablets

0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Yang Xiao, MD/PhD · Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04698330 on ClinicalTrials.gov